First Eagle Investment Management
ALNY icon

First Eagle Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

First Eagle Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-26,500
Closed -$2.88M – 99
2020
Q1 		$2.88M Buy
+26,500
New +$3.06M 0.01% 104

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

First Eagle Investment Management's ALNY Position: Q2 2020 in Review

First Eagle Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2020, closing a stake of 26,500 shares — an estimated $2.88M sold.

First Eagle Investment Management first reported a position in ALNY in Q1 2020 and held it in 1 quarter. The position peaked at $2.88M in Q1 2020. 374 funds tracked by Wall St. Rank hold ALNY as of Q2 2020.

  • First Eagle Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • First Eagle Investment Management sold 26,500 Alnylam Pharmaceuticals shares in Q2 2020, an estimated $2.88M.
  • First Eagle Investment Management first reported a position in Alnylam Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • First Eagle Investment Management's Alnylam Pharmaceuticals position peaked at $2.88M in Q1 2020.
  • 374 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2020.

Based on First Eagle Investment Management's 13F filing for Q2 2020, filed 10 Aug 2020.